AccurKardia key facts
- Developer of an ECG (Electrocardiogram)-based diagnostics software platform intended to enhance interpretation of electrocardiogram data for improved detection of cardiovascular and metabolic…
- It has raised $9.0M across 1 recorded rounds; the latest was Seed Round ($4.1M) in Aug 2022.
- Notable investors include MedTech Innovator, Mayo Clinic Platform, Popular.
- AccurKardia has filed 1 Form D with the SEC, most recently Jun 2023 ($4.1M sold to 41 investors).
- Status: Privately Held (backing).
Who backs AccurKardia
3- ·Watch AccurKardia: the Monday email on marks, rounds and moves
AccurKardia funding rounds
1 roundsHow much has AccurKardia raised?
AccurKardia has raised $9 million in total; 1 of its rounds is on record. The largest on record was a $4.1 million seed round in Aug 2022.
AccurKardia has filed 1 Form D with the SEC, most recently in Jun 2023 ($4.1 million sold to 41 investors).
AccurKardia investors
3 investors are on record for AccurKardia, including MedTech Innovator, Mayo Clinic Platform and Popular. The seed round in Aug 2022 drew 41 investors.
About AccurKardia
Developer of an ECG (Electrocardiogram)-based diagnostics software platform intended to enhance interpretation of electrocardiogram data for improved detection of cardiovascular and metabolic conditions. The company's platform offers automated ECG interpretation, cloud-based clinical integration, and AI (artificial intelligence) models for detecting electrolyte imbalance and structural heart disease, enabling healthcare providers and clinical teams to identify critical conditions earlier and improve patient care.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 29
- Website
- accurkardia.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
AccurKardia doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.